Pharmacopeial Forum 818 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] ERRATA

Similar documents
Compliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

INTERIM REVISION ANNOUNCEMENT

contents of the monograph in effect today. Please refer to the current edition of the USP NF for official text.

This revision also necessitates a change in the table numbering in the test for Organic Impurities.

ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) ARTESUNATI COMPRESSI ARTESUNATE TABLETS

Tramadol Hydrochloride Extended-Release Tablets. Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance

Revision Bulletin 28 Jul Aug 2017 Chemical Medicines Monographs 3

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

Quetiapine Tablets. Expert Committee Monographs Chemical Medicines 4 Reason for Revision Compliance

Should you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or

Telmisartan and Hydrochlorothiazide Tablets. Type of Posting. Revision Bulletin Posting Date. 26 Jan 2018 Official Date

Should you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

MONOGRAPHS (NF) Pharmacopeial Forum 616 HARMONIZATION Vol. 31(2) [Mar. Apr. 2005]

Diltiazem Hydrochloride Extended-Release Capsules. Type of Posting Posting Date Official Date

MONOGRAPHS (USP) Saccharin Sodium

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS

RITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)

Should you have any questions, please contact Gerald Hsu, Ph.D., Senior Scientific Liaison ( or

ARTENIMOLUM ARTENIMOL. Adopted revised text for addition to The International Pharmacopoeia

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

The Tacrolimus Capsules Revision Bulletin supersedes the currently official monograph.

Title Revision n date

Compliance. Minor editorial changes have been made to update the monograph to the current USP style.

Revision Bulletin 23 Feb Mar 2018 Chemical Medicines Monographs 3 Compliance

Minor editorial changes have been made to update the monograph to the current USP style.

BRIEFING Assay + + +

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT

International Journal of Pharma and Bio Sciences DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF STRONTIUM RANELATE IN SACHET

» Croscarmellose Sodium is a cross linked polymer of carboxymethylcellulose sodium.

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

U.S. Pharmacopeia Methods for HPLC

CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)

BRIEFING. Nonharmonized attributes: Identification, Heavy metals, Characters, Labeling, Bacterial endotoxins, Sterility, Storage.

» Monohydrate Citric Acid contains one molecule of water of hydration. It contains not less than 99.5 percent and not more than 100.

RP-HPLC Method Development and Validation of Abacavir Sulphate in Bulk and Tablet Dosage Form

Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica

Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin in Pharmaceutical Dosage Form using RP-HPLC Method

ASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF LACOSAMIDE IN BULK AND ITS PHARMACEUTICAL FORMULATION

Lutein Esters from Tagetes Erecta

E17 ETHYLCELLULOSE. Revision 3 Stage 4

Heparin Sodium ヘパリンナトリウム

Relative Measurement of Zeaxanthin Stereoisomers by Chiral HPLC

Tenofovir disoproxil fumarate (Tenofoviri disoproxili fumaras)

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)

Hyderabad, India. Department of Pharmaceutical Chemistry, Glocal University, Saharanpur, India.

Draft proposal for The International Pharmacopoeia

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.

Validation of Changes to the USP Assay Method for Ibuprofen Tablets

Should you have any questions, please contact Ravi Ravichandran, Principal Scientific Liaison ( or

Petrolatum. Stage 4, Revision 1. Petrolatum is a purified semi solid mixture of hydrocarbons obtained from petroleum.

Available online Research Article

IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page:

National Standard of the People s Republic of China. National food safety standard. Determination of pantothenic acid in foods for infants and

Change to read: BRIEFING

BRIEFING. Pharmacopeial Discussion Group Sign Off Document Attributes EP JP USP Definition Identification B Identification C + + +

Draft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution

HYDROXYPROPYLCELLULOSE, LOW SUBSTITUTED Stage 4, Revision 1 CP: USP BRIEFING NOTE

Development and Validation of a Simultaneous HPLC Method for Quantification of Amlodipine Besylate and Metoprolol Tartrate in Tablets

RP- HPLC and Visible Spectrophotometric methods for the Estimation of Meropenem in Pure and Pharmaceutical Formulations

Journal of Chemical and Pharmaceutical Research, 2018, 10(3): Research Article

Available online at Scholars Research Library

Simultaneous estimation of Metformin HCl and Sitagliptin in drug substance and drug products by RP-HPLC method

ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)

Development and validation of stability indicating RP-LC method for estimation of calcium dobesilate in pharmaceutical formulations

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)

NSave Nature to Survive VALA CLOVIR HYDROCHLORIDE

THERMALLY OXIDIZED SOYA BEAN OIL interacted with MONO- and DIGLYCERIDES of FATTY ACIDS

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column

REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM. (August 2010)

10 Sulfaquinoxaline H N O S O. 4-amino-N-quinoxalin-2-ylbenzenesulfonamide C 14 H 12 N 4 O 2 S MW: CAS No.:

Scholars Research Library. Der Pharmacia Lettre, 2015, 7 (5):44-49 (

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD ESTIMATION OF TOLVAPTAN IN BULK PHARMACEUTICAL FORMULATION

Purity Tests for Modified Starches

PAPRIKA EXTRACT SYNONYMS DEFINITION DESCRIPTION FUNCTIONAL USES CHARACTERISTICS

J Pharm Sci Bioscientific Res (4): ISSN NO

Pelagia Research Library

Journal of Chemical and Pharmaceutical Research, 2017, 9(9): Research Article

By Authority Of THE UNITED STATES OF AMERICA Legally Binding Document

Pelagia Research Library

Methotrexate. (Ph. Eur. monograph 0560) C 20 H 22 N 8 O Action and use. Dihydrofolate reductase inhibitor; cytostatic.

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)

The present work was aimed at developing a validated RP-UPLC method for simultaneous estimation of Sitagliptin (Anti

METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC FOR ESTIMATION OF ZOLPIDEM TARTARATE

CHAPTER 2 SIMULTANEOUS DETRMINATION OF ANASTROZOLE AND TEMOZOLOMIDE TEMOZOLOMIDE CAPSULES 20 MG AND ANASTROZOLE TABLETS 1 MG

Analytical method validation for tablet of phenoxymethyl penicillin potassium by RP-HPLC method

FLUNITRAZEPAM Latest Revision: January 24, 2006

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS

Corn Starch Analysis B-47-1 PHOSPHORUS

6.02 Uniformity of Dosage Units

Stability indicating RP-HPLC method development and validation of Etizolam and Propranolol hydrochloride in pharmaceutical dosage form

Photosensitivity of Internal Standard Valerophenone

ISSN (Print)

Development, Estimation and Validation of Lisinopril in Bulk and its Pharmaceutical Formulation by HPLC Method

COMMENTARY TO USP31 - NF26

ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012)

International Journal of Medicine and Pharmaceutical Research. International Journal of Medicine and Pharmaceutical Research

Transcription:

818 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] ERRATA Following is a list of errata and corrections to USP NF. The page number indicates where the item is found and in which official or pending official publication of USP NF. If necessary, this list will be updated with every issue of PF. This information will also be available as a cumulative table in future Supplements and will appear in its corrected form in a future annual edition of USP NF. Errata are considered to be items erroneously published that have not received the approval of the Council of Experts and that do not reflect the official requirement. USP staff is available to respond to questions regarding the accuracy of a particular requirement by calling 1-800-822-USPC. 310 h788i Particulate Matter in Injections Introduction Second paragraph, line 2: Change of mobile undissolved particles, of extraneous mobile undissolved particles, 1178 Butylated Hydroxytoluene Related compounds Line 1 under Potassium ferricyanide solution: Change 50 mg 500 mg Line 1 under Ferric chloride solution: Change 105 mg 1050 mg 1855 Cefprozil Chemical names Change the first chemical name to read: 5-Thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7- [[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3- (1-propenyl)-, monohydrate, [6R-[6a,7b(R*)]]- Change the second chemical name to read: (6R,7R)-7-[(R)-2-Amino-2-(p-hydroxyphenyl)acetamido]-8-oxo-3-propenyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate

Vol. 35(4) [July Aug. 2009] INTERIM REVISION ANNOUNCEMENT 819 1948 Citalopram Hydrobromide Related compounds Table 1 referenced under TEST 1, Procedure, appears at the bottom of page 1950. 2906 Metformin Hydrochloride Tablets Dissolution h711i Insert Test 3, official in Second IRA of 2007. TEST 3 If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 3. Medium: ph 6.8 phosphate buffer; 1000 ml. Apparatus 1: 100 rpm. Time: 60 minutes. Determine the amount of C 4 H 11 N 5 HCl dissolved by employing the following method. 0.05 M Sodium phosphate with 1-pentanesulfonic acid solution Dissolve 1.38 g of monobasic sodium phosphate in about 1800 ml of water. Add 3.484 g of 1-pentanesulfonic acid sodium salt, and mix. Adjust with diluted phosphoric acid to a ph of 3.00 + 0.05. Add water to make 2000 ml, and mix. Mobile phase Prepare a filtered and degassed mixture of 0.05 M Sodium phosphate with 1-pentanesulfonic acid solution and acetonitrile (19:1). Make adjustments if necessary (see System Suitability under Chromatography h621i). Standard stock solution Transfer about 25 mg, accurately weighed, of USP Metformin Hydrochloride RS to a 100-mL volumetric flask, and add about 50 ml of Medium. Sonicate until dissolved, and dilute with Medium to volume. Standard solution Transfer 10.0 ml of the Standard stock solution to a 50-mL volumetric flask, and dilute with Medium to volume. Test solution Withdraw a portion of the solution under test, and pass through a 0.45-mm nylon filter. Dilute with Medium, if necessary, to obtain a concentration similar to that of the Standard solution. Chromatographic system The liquid chromatograph is equipped with a 230-nm detector and a 4.6-mm 6 25-cm column that contains 5-mm packing L1. The flow rate is about 1.0 ml per minute. Chromatograph replicate injections of the Standard solution, and record the peak responses as directed for Procedure: the tailing factor is not more than 2.0; the column efficiency is not less than 1500 theoretical plates; and the relative standard deviation for replicate injections is not more than 2.0%. Procedure Separately inject equal volumes (about 40 ml) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the percentage of metformin released by the formula: in which r U and r S are the peak responses obtained from the Test solution and the Standard solution, respectively; C S is the concentration, in mg per ml, of metformin in the Standard solution; 900 is the volume, in ml, of Medium; 100 is the conversion factor to percentage; D is the dilution factor of the Test solution; and LC is the Tablet label claim, in mg. Tolerances Not less than 70% (Q) of the labeled amount of C 4 H 11 N 5 HCl is dissolved in 60 minutes.

820 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] 3372 Prednisolone Sodium Phosphate Related compounds Line 1 under Test solution: Change Accurately weigh a known quantity of USP Prednisolone Sodium Phosphate RS Accurately weigh a known quantity of prednisolone sodium phosphate 3374 Prednisolone Sodium Phosphate Injection Identification Change: B: It responds to Identification test A under Prednisolone Sodium Phosphate. B: Infrared Absorption h197ki Test specimen: Place 5 ml of the Assay preparation obtained as directed in the Assay, in a glass-stoppered, 100-mL volumetric flask, mix with 5 ml of Alkaline phosphatase solution prepared as directed in the Assay, and add 50 ml of methylene chloride. Insert the stopper, and allow to stand, with occasional gentle inversion (about once every 15 minutes), for 2 hours. Filter the methylene chloride layer through a dry paper, and evaporate 25 ml of the filtrate to dryness. Standard specimen: Prepare as directed in Infrared Absorption h197ki, using USP Prednisolone RS.

Vol. 35(4) [July Aug. 2009] INTERIM REVISION ANNOUNCEMENT 821 Assay Change ph 9 Buffer with magnesium Prepare as directed in the Assay under Prednisolone Sodium Phosphate. ph 9 Buffer with magnesium Mix 3.1 g of boric acid and 500 ml of water in a 1-L volumetric flask, add 21 ml of 1 N sodium hydroxide and 10 ml of 0.1 M magnesium chloride, dilute with water to volume, and mix. Change Alkaline phosphatase solution Prepare as directed in the Assay under Prednisolone Sodium Phosphate. Alkaline phosphatase solution Transfer 250 mg of alkaline phosphate enzyme to a 25-mL volumetric flask, dissolve by adding ph 9 Buffer with magnesium to volume, and mix. Prepare this solution fresh daily. Change: Standard preparation Prepare as directed in the Assay under Prednisolone Sodium Phosphate. Standard preparation Dissolve a suitable, accurately weighed quantity of USP Prednisolone RS in methylene chloride, and dilute quantitatively and stepwise with methylene chloride to obtain a solution having a known concentration of about 16 mg per ml. Pipet 100 ml of the solution into a glass-stoppered, 100-mL cylinder, and add 1.0 ml of Alkaline phosphatase solution and 1.0 ml of water. Allow to stand, with occasional gentle inversion, for 2 hours. Change: Procedure Proceed as directed for Procedure in the Assay under Prednisolone Sodium Phosphate. Procedure Pipet 1 ml of the Assay preparation into a glass-stoppered, 100-mL cylinder, add 1.0 ml of Alkaline phosphatase solution and about 50 ml of methylene chloride, insert the stopper, and allow to stand, with occasional gentle inversion (about once every 15 minutes), for 2 hours. Add methylene chloride to volume, mix, and allow to stand until the methylene chloride layer is clear (about 20 minutes). Concomitantly and without delay, determine the absorbances of the methylene chloride solution obtained from the Assay preparation and the Standard preparation at 241 nm, with a suitable spectrophotometer, using methylene chloride as the blank.

822 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] 3375 Prednisolone Sodium Phosphate Ophthalmic Solution Identification Change: Identification It responds to Identification test A under Prednisolone Sodium Phosphate and to Identification test A under Prednisolone Sodium Phosphate Injection. Identification A: Infrared Absorption h197ki Test specimen: Place 5 ml of the Assay preparation obtained as directed in the Assay, in a glass-stoppered, 100-mL volumetric flask, mix with 5 ml of Alkaline phosphatase solution prepared as directed in the Assay, and add 50 ml of methylene chloride. Insert the stopper, and allow to stand, with occasional gentle inversion (about once every 15 minutes), for 2 hours. Filter the methylene chloride layer through a dry paper, and evaporate 25 ml of the filtrate to dryness. Standard specimen: Prepare as directed in Infrared Absorption h197ki, using USP Prednisolone RS. B: Dissolve 65 mg of phenylhydrazine hydrochloride in 100 ml of dilute sulfuric acid (3 in 5), add 5 ml of isopropyl alcohol, and mix. Heat 5 ml of this solution with 1 ml of Assay preparation (obtained as directed in the Assay) at708 for 2 hours: a yellow color develops. First Supplement to 4031 Betamethasone Oral Solution Assay Line 1 under Standard stock preparation: Change Dissolve an accurately weighed quantity of USP Betamethasone RS in alcohol, Dissolve an accurately weighed quantity of USP Betamethasone RS in dehydrated alcohol, Line 1 under System suitability preparation: Change Dissolve an accurately weighed quantity of betamethasone in alcohol, Dissolve an accurately weighed quantity of betamethasone in dehydrated alcohol,